Unknown Manufacturer
Parkinson's disease results from degeneration of the dopaminergic cells in the substantia nigra. Several dopamine receptor agonists have been used as antiparkinsonian therapy. Sumanirole is a dopamine receptor agonist with a high selectivity for the D2 receptor subtype over the other closely related D3 and D4 receptor subtypes.
Investigated for use/treatment in parkinson's disease.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
